Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3937

Provisional Schedule

Expected publication 29 June 2022

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors Takeda (teduglutide)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Patients On Intravenous & Nasogastric Nutrition Therapy (PINNT)
  Short Bowel Survivors & Friends
Professional groups Northwick Park and St Mark's Hospital
  Royal College of Physicians
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (cimetidine, omeprazole, ranitidine) - not participating
  Allergan (lansoprazole, omeprazole) - not participating
  Alliance pharmaceuticals (ranitidine) - not participating
  AstraZeneca (omeprazole) - not participating
  Aurobindo Pharma (ranitidine) - not participating
  Bristol Laboratories (ranitidine) - not participating
  Chugai Pharma (sucralfate) - not participating
  Concordia International (ranitidine) - not participating
  Dexcel Pharma (omeprazole) - not participating
  Dr Reddy’s Laboratories (omeprazole) - not participating
  GlaxoSmithKline (ranitidine) - not participating
  Janssen-Cilag (loperamide)- not participating
  Lupin (lansoprazole) - not participating
  McNeil Products (loperamide) - not participating
  Omega Pharma (ranitidine) - not participating
  Pfizer (lansoprazole)
  Reckitt Benckiser Healthcare (loperamide, ranitidine) - not participating
  Rosemont (cimetidine, ranitidine) - not participating
  Sandoz (omeprazole) - not participating
  The Boots Company (loperamide, omeprazole, ranitidine) - not participating
  Wockhardt UK (loperamide) - not participating
  Zentiva (lansoprazole, loperamide, omeprazole) - not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
12 April 2022 Committee meeting: 2
11 March 2022 - 01 April 2022 Draft guidance
15 February 2022 Committee meeting: 1
15 June 2021 Invitation to participate
19 April 2021 - 18 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1
19 April 2021 In progress. Topic in progress

For further information on our processes and methods, please see our CHTE processes and methods manual